Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer

Published:2015-12 Issue:3 Volume:90 Page:410-416
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Kusagaya Hideki,Inui Naoki,Karayama Masato,Fujisawa Tomoyuki,Enomoto Noriyuki,Kuroishi Shigeki,Nakamura Yutaro,Matsuda Hiroyuki,Yokomura Koshi,Koshimizu Naoki,Toyoshima Mikio,Imokawa Shiro,Yamada Takashi,Shirai Toshihiro,Hayakawa Hiroshi,Suda Takafumi

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Management of non-small-cell lung cancer: recent developments;Reck;Lancet,2013

2. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J. Clin. Oncol.,2009

3. Chemotherapy-induced nausea and vomiting;Hesketh;N. Engl. J. Med.,2008

4. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference;Roila;Ann. Oncol.,2010

5. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment;Bloechl-Daum;J. Clin. Oncol.,2006

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology;International Journal of Clinical Oncology;2024-09-11

2. Defining the Clinical Benefits of Adding a Neurokinin-1 Receptor Antagonist to Control Chemotherapy-Induced Nausea and Vomiting in Moderately Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology;2024-08-19

3. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial;Journal of Clinical Oncology;2024-08-10

4. Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy;Biological and Pharmaceutical Bulletin;2024-06-19

5. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial;Lung Cancer;2024-06